Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07760246
PHASE1

A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart

Sponsor: Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

The main objective of this trial is to evaluate the effects of verducatib in the range of therapeutic to supra-therapeutic exposures on the QT/QTc-interval and other ECG parameters

Official title: A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group Design Trial With Moxifloxacin as Positive Control in a Nested Crossover to Evaluate the Effects of Multiple Doses of Verducatib (BI 1291583) on Cardiac Safety Parameters in Healthy Male and Female Trial Participants

Key Details

Gender

All

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

56

Start Date

2026-08-20

Completion Date

2026-12-30

Last Updated

2026-09-09

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Verducatib

Verducatib

DRUG

Moxifloxacin

Moxifloxacin

DRUG

Placebo resembling Verducatib

Placebo resembling Verducatib

DRUG

Placebo resembling Moxifloxacin

Placebo resembling Moxifloxacin

Locations (1)

CRS Clinical Research Services Mannheim GmbH

Mannheim, Germany